Bone Biologics (BBLGW) CEO shares letter to stockholders via press release

Rhea-AI Filing Summary

Bone Biologics Corporation filed a current report to share that its Chief Executive Officer issued a letter to stockholders. On September 4, 2025, the company released a press release discussing this CEO letter, and that press release is attached as Exhibit 99.1 to the report and incorporated by reference. The company’s common stock and related warrants trade on the Nasdaq Capital Market under the symbols BBLG and BBLGW, respectively.

false 0001419554 0001419554 2025-09-04 2025-09-04 0001419554 BBLG:CommonStockParValue0.001PerShareMember 2025-09-04 2025-09-04 0001419554 BBLG:WarrantsToPurchaseCommonStock0.001ParValuePerShareMember 2025-09-04 2025-09-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 4, 2025

BONE BIOLOGICS CORPORATION

(Exact name of registrant as specified in its charter)

Delaware		001-40899		42-1743430
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

2 Burlington Woods Drive, Ste. 100 Burlington, MA		01803
(Address of principal executive offices)		(Zip Code)

(Registrant’s telephone number, including area code): (781) 552-4452

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		BBLG		Nasdaq Capital Market
Warrants to Purchase Common Stock, $0.001 par value per share		BBLGW		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On September 4, 2025, the Company issued a press release with respect to the CEO’s Letter to Stockholders. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
99.1		Press Release Bone Biologics CEO Issues Letter to Stockholders, dated September 4, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	BONE BIOLOGICS CORPORATION
Date: September 4, 2025
	By:	/s/ Jeffrey Frelick
		Jeffrey Frelick
		Chief Executive Officer

FAQ

What did Bone Biologics Corporation (BBLGW) disclose in this 8-K?

Bone Biologics Corporation disclosed that it issued a press release on September 4, 2025 relating to the CEO’s letter to stockholders. The press release is attached as Exhibit 99.1.

What is Exhibit 99.1 in Bone Biologics Corporation’s 8-K?

Exhibit 99.1 is titled “Press Release Bone Biologics CEO Issues Letter to Stockholders, dated September 4, 2025” and contains the company’s press release about the CEO’s letter.

Which stock and warrant symbols are associated with Bone Biologics Corporation?

Bone Biologics Corporation’s common stock trades under the symbol BBLG, and its warrants to purchase common stock trade under the symbol BBLGW on the Nasdaq Capital Market.

Under which item of Form 8-K did Bone Biologics report the CEO letter press release?

The company reported the CEO letter press release under Item 7.01 Regulation FD Disclosure, indicating it is providing information for fair disclosure to the market.

Who signed the Bone Biologics Corporation 8-K related to the CEO letter?

The report was signed on behalf of Bone Biologics Corporation by Jeffrey Frelick, who is identified as the company’s Chief Executive Officer, dated September 4, 2025.

Where is Bone Biologics Corporation headquartered as stated in this filing?

The company lists its principal executive offices at 2 Burlington Woods Drive, Ste. 100, Burlington, MA 01803, as stated in the report.